FathomX, a Singapore-based digital health AI company and a spin-off company from the National University of Singapore (NUS) and National University Health System (NUHS), recently raised a pre-series A fund of SGD$ 2.24 million in the lead-up to Series A funding.

Through this funding, the company will be able to harness the full potential of its digital AI solution to read medical images, including mammograms. 

The funding will further accelerate the pace of product development, and regulatory approvals and broaden the platform for research and commercial collaborations. It will also facilitate the ongoing multi-center validation study across eight regions in the Asia-Pacific.

FathomX aims to increase the accuracy of mammograms in breast cancer detection using AI-integrated devices for detection, prevention, and diagnostics. FxMammo has several important clinically validated features, specifically a reduction in false positives and interval cancers. 

Company: FathomX Pte Ltd

Raised: SGD$ 2.24

Round: pre-Series A

Funding Month: Aug 2022

Lead Investors: Undisclosed

Additional Investors: 

Company Website: https://www.fathomx.co/

Software Category: Digital Health AI Solutions

About the Company: FathomX is a MedTech AI spin-off from the National University of Singapore and the National University Health System that aims to deploy clinician-friendly solutions to enhance the existing workflow and aims to develop a range of AI technologies in the field of breast cancer. The company develops knowledge, capabilities, and value through collaborations with research and healthcare institutions, deployment and teleradiology partners, as well as picture archiving and communication systems (PACS). The company's flagship product, FxMammo, is an AI Assistant that significantly improves the screening procedure for mammograms by reducing the false positive/negative rates and enhancing the clinical workflow by reducing the time taken to assess a screen as well as the number of radiologists required per screen. FathomX works closely with global solutions provider HP Enterprise to develop a range of technologies in the field of medical imaging and has integrated its AI engines into a technical infrastructure that is scalable, customizable, and already tested out in various hospitals and clinics.

Source: https://en.prnasia.com/releases/apac/breast-cancer-ai-company-fathomx-raises-sgd-2-24-million-in-pre-series-a-funding-373796.shtml